山东大学耳鼻喉眼学报 ›› 2017, Vol. 31 ›› Issue (5): 72-78.doi: 10.6040/j.issn.1673-3770.0.2017.297

• 论著 • 上一篇    下一篇

一氧化氮对鼻咽癌CNE-2细胞株化疗增敏效应的研究

张彩霞1,2,刘阳云1,江文1,刘庚勋1,曹杭1,陈琼1,张纪帅1   

  1. 1.解放军第一六三中心医院/湖南师范大学医学院第二附属医院 耳鼻咽喉头颈外科, 湖南 长沙 410003;
    2.广西医科大学第四附属医院 柳州市工人医院耳鼻咽喉头颈外科, 广西 柳州 545000
  • 收稿日期:2017-07-07 出版日期:2017-10-16 发布日期:2017-10-16
  • 通讯作者: 刘阳云. E-mail:879418362@qq.com
  • 基金资助:
    湖南省教育厅科研项目(14C0697)

Investigation of chemosensitization induced by nitric oxide on nasopharyngeal carcinoma CNE-2 cells.

ZHANG Caixia1,2, LIU Yangyun1, JIANG Wen1, LIU Gengxun1, CAO Hang1, CHEN Qiong1, ZHANG Jishuai1   

  1. Department of Otolaryngology, 1. No.163 Hospital of PLA /The Second Affiliated Hospital of Hunan Normal University Medical College, Changsha 410003, Hunan, China;2. Liuzhou Workers Hospital / Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545000, Guangxi, China
  • Received:2017-07-07 Online:2017-10-16 Published:2017-10-16

PDF (PC)

494

摘要： 目的 探讨外源性一氧化氮(NO)在顺铂(DDP)作用于CNE-2细胞的过程中是否存在增敏效应,为提高鼻咽癌化疗疗效提供实验和理论依据。 方法 分别使用不同浓度NO供体药物硝普钠(SNP)、DDP及二者联合干预CNE-2细胞,采用硝酸还原酶法检测NO的浓度,镜下观察细胞形态学变化,CCK-8法检测细胞增殖抑制率以及流式细胞仪检测细胞凋亡。 结果 (1) SNP呈浓度依赖方式抑制CNE-2细胞的增殖、促进凋亡;(2) 上清液中NO浓度与SNP浓度呈正相关,有统计学意义(r=0.968, P<0.001);(3) DDP+SNP联合组与SNP组和DDP组相比,CNE-2细胞形态学差异显著, 漂浮细胞显著增多,贴壁数量逐渐减少并失去原有形态;(4) 当SNP 600 μmol/L时对细胞增殖无明显影响,然而联合DDP后较单用DDP组细胞抑制率显著提高(t=9.049, P<0.001);(5) SNP组与DDP联用时CNE-2细胞凋亡率上升,较单用SNP、DDP组显著增强(t=-19.816, P<0.001; t=-5.242, P=0.035)。 结论 外源性NO能抑制CNE-2的增殖,其抑制效应与NO浓度呈正相关;合适浓度的外源性NO可在对细胞本身不产生明显毒性的情况下显著增强DDP对CNE-2细胞株的化疗敏感性。

关键词: 鼻咽癌, 顺铂, 化疗增敏, 一氧化氮, 硝普钠, 凋亡

Abstract: Objective To investigate whether exogenous nitric oxide(NO)could increase chemosensitization to cisplatin(DDP)in CNE2 cells, and to provide an experimental and theoretical basis for improving the effectiveness of chemotherapy for nasopharyngeal carcinoma. Methods CNE-2 cells were treated with various concentrations of sodium nitroprusside(SNP), DDP, and both chemicals. The nitrate reductase method was used to detect the concentration of NO. Morphological changes of cells were observed using an inverted phase contrast microscope and CCK8 assays were used to examine the viability of cells. Flow cytometry was applied to detect apoptosis in NPC cells. Results (1)The concentration of NO was positively correlated with the concentration of SNP, and this correlation was statistically significant(r=0.968, P<0.05).(2)Compared with the CNE-2 cells in the SNP group, DDP group, and control group, the CNE-2 cells in the DDP+SNP group showed more extensive morphological changes.(3)The inhibitory effects of SNP+DDP were significantly greater than those of SNP or DDP alone(P<0.05).(4)Compared with the groups treated with SNP or DDP individually, flow cytometry showed that the apoptosis rate of CNE-2 cells was significantly higher in the group treated with both SNP and DDP(P<0.05). Conclusion Exogenous NO can inhibit CNE-2 proliferation, and the inhibitory effect was positively correlated with the concentration of NO. The proper concentration of exogenous NO can significantly enhance the chemosensitivity of CNE-2 cells to DDP, without substantial toxicity.

Key words: Nasopharyngeal carcinoma, Sodium nitroprusside, Cis-platinum, Apoptosis, Chemosensitization, Nitric oxide

中图分类号: 

  • R739.62
[1] Tan G, Tang X, Tang F. The role of microRNAs in nasopharyngeal carcinoma[J]. Tumour Biol, 2015, 36(1):69-79.
[2] Razak AR, Siu LL, Liu FF, et al. Nasopharyngeal carcinoma: the next challenges[J]. Eur J Cancer, 2010, 46(11):1967-1978.
[3] Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer[J]. Semin Radiat Oncol, 2012, 22(3):233-244.
[4] Perri F, Bosso D, Buonerba C, et al. Locally advanced nasopharyngeal carcinoma: current and emerging treatment strategies[J]. World J Clin Oncol, 2011, 2(12):377-383.
[5] Zhang L, Chen QY, Liu H, et al. Emerging treatment options for nasopharyngeal carcinoma[J]. Drug Des Devel Ther, 2013, 7(2):37-52.
[6] 张彩霞, 刘阳云. 一氧化氮对肿瘤细胞化疗增敏机制研究进展[J]. 临床与病理杂志,2016,36(8):1224-1229. ZHANG Caixia, LIU Yangyun. Research progress of nitric oxide chemosensitization mechanisms on tumor cells[J]. Inter J Pathol Clin Med, 2013, 7(2):37-52.
[7] Yang L, Lan C, Fang Y, et al. Sodium nitroprusside(SNP)sensitizes human gastric cancer cells to TRAIL-induced apoptosis[J]. Int Immunopharmacol, 2013, 17(2):383-389.
[8] Seabra AB, de Lima R, Calderón M. Nitric oxide releasing nanomaterials for cancer treatment: current status and perspectives[J]. Curr Top Med Chem, 2015, 15(4):298-308.
[9] Zhang HX, Deng C, Liu OS, et al. Inducible nitric oxide inhibitor enhances the anti-tumor effect of cisplatin on CNE-2 cells by inducing cell apoptosis[J]. Eur Rev Med Pharmacol Sci, 2014, 18(19):2789-2797.
[10] 刘阳云, 赵素萍, 刘庚勋, 等. 诱导型一氧化氮合酶在指导晚期鼻咽癌治疗方案选择中的价值[J]. 中国癌症杂志,2007,17(9):684-688. LIU Yangyun, ZHAO Suping, LIU Gengxun, et al. The value of inducible nitric oxide synthase to select the project of treatment in nasopharyngeal carcinoma[J]. Chin Oncol, 2007, 17(9):684-688.
[11] 刘阳云, 赵素萍, 刘庚勋, 等. 诱导型一氧化氮合酶与环氧合酶-2在鼻咽癌中表达的初步研究[J]. 中华放射肿瘤学杂志,2007,16(2):155-156.
[12] Mocellin S. Nitric oxide: cancer target or anticancer agent?[J]. Curr Cancer Drug Targets, 2009, 9(2):214-236.
[13] 张彩霞,刘阳云. 一氧化氮供体型化合物化疗增敏效应[J]. 国际肿瘤学杂志,2016,43(9):53-56. ZHANG Caixia, LIU Yangyun. Neoplasms chemosensitization enhancing effects of nitric oxide donor compounds[J]. J Int Oncol, 2016, 43(9):53-56.
[14] Hirst D, Robson T. Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapy[J]. Curr Pharm Des, 2010, 16(4):411-420.
[15] Carradori S, Mollica A, Monte CD, et al. Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis[J]. Molecules, 2015, 20(4):5667-5679.
[16] Reynolds MM, Witzeling SD, Damodaran VB, et al. Applications for nitric oxide in halting proliferation of tumor cells[J]. Biochem Biophys Res Commun, 2013, 4(31):647-651.
[17] Persson PB, Bondke Persson A. Nitric oxide: a classic revisited[J]. Acta Physiol, 2013, 207(3):427-429.
[18] Aranda E, López-Pedrera C, De La Haba-Rodriguez JR, et al. Nitric oxide and cancer: the emerging role of S-nitrosylation[J]. Curr Mol Med, 2012, 12(1):50-67.
[19] Singh S, Gupta AK. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies[J]. Cancer Chemother Pharmacol, 2011, 67(6):1211-1224.
[20] González R1, Ferrín G, Aguilar-Melero P, et al. Targeting hepatoma using nitric oxide donor strategies[J]. Antioxid Redox Signal, 2013, 18(5):491-506.
[21] Huerta-Yepez S, Baritaki S, Baay-Guzman G, et al. Contribution of either YY1 or Bcl XL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer[J]. Nitric Oxide Soc, 2013, 29(1):17-24.
[22] Bian K, Murad F. sGC-cGMP signaling: target for anticancer therapy[J]. Adv Exp Med Biol, 2014, 14(8):5-13.
[23] Bian K, Murad F. What is next in nitric oxide research? From cardiovascularsystem to cancer biology[J]. Nitric Oxide, 2014, 4(3):3-7.
[24] Bonavida B, Garban H. Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics[J]. Redox Biol, 2015, 10(6):486-494.
[25] Sarti P, Forte E, Mastronicola D, et al. Cytochrome c oxidaseand nitric oxide in action: molecular mechanisms and pathophysiological implications[J]. Biochim Biophys Acta, 2012, 18(7):610-619.
[26] Bonavida B, Baritaki S. The novel role of yin yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN circuitry[J]. Crit Rev Oncog, 2011, 16(4):211-226.
[27] Baritaki S, Huerta-Yepez S, Sahakyan A, et al. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer snail and induction of the metastasis-suppressor RKIP[J]. Cell Cycle, 2010, 12(9):4931-4940.
[28] Tang H, Park S, Sun SC, et al. Kolcgnaling components of the IκB kinase complex[J]. FEBS Lett, 2010, 5(8):662-668.
[29] Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3 CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer[J]. J Clin Oncol, 2013, 31(4):4297-4234.
[1] 林小雪,林葆睿,李佩珊,卢标清. 电子鼻咽镜联合窄带成像技术在鼻咽癌中医辨证中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 40-46.
[2] 张潇涵,朱立亚,肖雨,付小龙. 利用腺相关病毒AAV1探究顺铂诱导的血管纹损伤中Gasdermin D的作用机制[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 29-34.
[3] 王盛,李银丹,杨金姬. microRNA在鼻咽癌中的作用及其研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 125-131.
[4] 邱前辉,肖旭平,杨钦泰,叶菁,邓泽义,王德生,谭国林,蒋卫红,卢永田,唐隽,石照辉,邓晓聪,刘遗斌,王跃武,段传志,杜德坤,白小欣,陈文伙,莫立根,蔡楚伟,曾鹏,何旭英,杨一梅,赵洲洋,陈健龙,赵充,林志雄,李先明,李曙平,陈冬平,陈勇,黄莹,陈春燕,韩非,黄理金,瞿申红. 鼻咽癌治疗后并发颈动脉爆裂综合征的临床处理专家共识[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 1-18.
[5] 王思权,朱洪申,张晓斌,赵洲洋,马跃,杨一梅,黄理金. 放射治疗后鼻咽癌患者单侧颈内动脉栓塞术后脑卒中及颅神经麻痹的相关因素分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 19-25.
[6] 黄巧,任毅,侯涛,廖行伟,朱子昂,詹晓琳,刘盈,尹时华. 鼻咽癌组织中EphB2表达及与临床病理特征的相关性[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 26-30.
[7] 孙春晓,王文晴,岳田,刘济生. 高低累积顺铂剂量同步放化疗治疗鼻咽癌的疗效分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 31-41.
[8] 徐飞,朱光熹,王可心. 基于决策树算法构建鼻咽癌患者放疗后发生放射性口腔黏膜炎风险的预测模型[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 42-48.
[9] 王再兴,唐志元,李定波,石照辉,曾宪海,张秋航. 鼻咽癌放疗后肿瘤复发及颅底骨坏死引起颈内动脉破裂的治疗方案[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 49-58.
[10] 孙芳,谢楚波,邱前辉. 营养指标对鼻咽癌放射性颅底坏死患者创面修复影响的回顾性分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 59-68.
[11] 朱瑞楷,吴家荣,孙芳,谢楚波,邱前辉. 基于计算机断层扫描血管造影术评估鼻咽癌放疗后引起颈内动脉狭窄状况及其影响因素的研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 77-84.
[12] 覃德波,薛建成,杨文月,胡兵,陈涛,俞艳萍,孟庆国,孙焕吉,苗北平,卢永田. 鼻咽癌诊疗变革:生物标志物与鼻内镜手术协同推进早期治疗发展[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 85-92.
[13] 吴家荣,邱前辉. 颅底筋膜组织在早期复发性鼻咽癌内镜手术中的临床意义[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 108-113.
[14] 陈铭,柯冰冰,崔雅琦,吴翠萍,陈正侬,李春燕,殷善开. NAD+对顺铂所致毛细胞氧化应激损伤的拮抗作用及相关基因表达调控[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 11-18.
[15] 杨鸣,刘雪霞,张华. m6A识别蛋白IGF2BPs家族在头颈肿瘤中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 153-161.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发